Secor Capital Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

Secor Capital Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-41,269	Closed	-$120K	–	651
2018 Q4	$120K	Sell	41,269 -82,027	-67%	-$225K	0.02%	446
2018 Q3	$324K	Sell	123,296 -45,483	-27%	-$112K	0.04%	361
2018 Q2	$395K	Sell	168,779 -61,638	-27%	-$172K	0.03%	413
2018 Q1	$677K	Sell	230,417 -1,425	-0.6%	-$3.89K	0.06%	341
2017 Q4	$635K	Buy	231,842 +12,993	+6%	+$39.9K	0.03%	336
2017 Q3	$742K	Sell	218,849 -180,594	-45%	-$502K	0.07%	301
2017 Q2	$987K	Sell	399,443 -10,880	-3%	-$25K	0.09%	274
2017 Q1	$931K	Hold	410,323	–	–	0.1%	250
2016 Q4	$870K	Buy	410,323 +26,352	+7%	+$73.5K	0.11%	258
2016 Q3	$1.29M	Buy	383,971 +242,707	+172%	+$770K	0.14%	215
2016 Q2	$444K	Buy	141,264 +31,111	+28%	+$104K	0.06%	424
2016 Q1	$367K	Sell	110,153 -94,209	-46%	-$294K	0.05%	393
2015 Q4	$723K	Buy	204,362 +167,374	+453%	+$701K	0.2%	170
2015 Q3	$186K	Buy	+36,988	New	+$212K	0.06%	446
2014 Q1	–	Sell	-60,054	Closed	-$507K	–	468
2013 Q4	$507K	Buy	+60,054	New	+$506K	0.2%	200

Other funds holding PDLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Secor Capital Advisors's PDLI Position: Q1 2019 in Review

Secor Capital Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q1 2019, closing a stake of 41,269 shares — an estimated $120K sold.

Secor Capital Advisors first reported a position in PDLI in Q4 2013 and held it in 15 quarters. The position peaked at $1.29M in Q3 2016. 157 funds tracked by Wall St. Rank hold PDLI as of Q1 2019.

Secor Capital Advisors reported no remaining PDL BioPharma, Inc. position as of Q1 2019 after selling out during the quarter.
Secor Capital Advisors sold 41,269 PDL BioPharma, Inc. shares in Q1 2019, an estimated $120K.
Secor Capital Advisors first reported a position in PDL BioPharma, Inc. in Q4 2013 and held it in 15 quarters.
Secor Capital Advisors's PDL BioPharma, Inc. position peaked at $1.29M in Q3 2016.
157 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2019.

Based on Secor Capital Advisors's 13F filing for Q1 2019, filed 15 May 2019.